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Background: Vertebrate organogenesis is a highly complex process involving sequential cascades of transcription
factor activation or repression. Interestingly a single developmental control gene can occasionally be essential for
the morphogenesis and differentiation of tissues and organs arising from vastly disparate embryological lineages.
Results: Here we elucidated the role of the mammalian homeobox gene Bapx1 during the embryogenesis of five
distinct organs at E12.5 - vertebral column, spleen, gut, forelimb and hindlimb - using expression profiling of sorted
wildtype and mutant cells combined with genome wide binding site analysis. Furthermore we analyzed the
development of the vertebral column at the molecular level by combining transcriptional profiling and genome
wide binding data for Bapx1 with similarly generated data sets for Sox9 to assemble a detailed gene regulatory
network revealing genes previously not reported to be controlled by either of these two transcription factors.
Conclusions: The gene regulatory network appears to control cell fate decisions and morphogenesis in the
vertebral column along with the prevention of premature chondrocyte differentiation thus providing a detailed
molecular view of vertebral column development.
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Vertebrate development is a complex, sequential process,
which is guided and controlled by a large number of tran-
scription factors acting in a spatio-temporal manner.
Many of these transcription factors are pleiotropic in na-
ture, expressing and functioning in multiple tissues simul-
taneously. Pleiotropy is a feature of some genes, which
refers to the ability to affect multiple, distinct and unre-
lated phenotypes and has important implications in devel-
opment, disease and evolution [1-4]. Although pleiotropy
has been studied over a period of time for genes involved* Correspondence: tlufkin@clarkson.edu
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article, unless otherwise stated.in various biological functions, very few in-depth molecu-
lar studies have been conducted looking at a single gene in
detail covering its roles in multiple tissues and trying to
understand the independent and /or overlapping molecu-
lar mechanisms involved in its disparate functions.
The mammalian homeobox gene Bapx1 (Nkx3.2) en-
codes a transcription factor that belongs to the eponymous
Nkx [5] gene family ortholog of the Drosophila bap gene
[6,7]. During mouse embryogenesis Bapx1 is expressed in
five distinct tissues - vertebral column, spleen, gut, fore-
limb and hindlimb, yet appears to have a unique function
in only a subset of these. Bapx1 null mice are affected by
lethal skeletal dysplasia, with severe malformation or ab-
sence of specific bones of the vertebral column and cranial
bones of mesodermal origin. The most severely affectedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in close proximity to the notochord. Bapx1 null mutants
also show visceral mesoderm defects leading to asplenia
[8-12]. The Bapx1 null embryos exhibit a shortened anter-
ior gut segment and a loss of the pyloric constriction [11].
Although Bapx1 is expressed in the developing limbs there
is no overt limb phenotype in the loss-of-function mutants
but a Bapx1 gain-of-function mouse model exhibits preax-
ial polydactyly and hypoplasia of the tibia [13].
Since Bapx1 is expressed in five distinct tissues it was
imperative to segregate these tissues as well as the spe-
cific cell type within the tissues expressing Bapx1 for a
detailed understanding of its molecular mechanism. We
achieved this by targeting the Bapx1 locus with enhanced
green fluorescent protein (EGFP) driven by an IRES
(Bapx1+/tm2.Tlu) into the 3’UTR of Bapx1 allowing for
mice of a wildtype genotype expressing both Bapx1 and
EGFP proteins or by inserting EGFP immediately after the
translational start codon of Bapx1 (Bapx1tm4.Tlu/tm4.Tlu) to
create a null genotype. In both cases EGFP was expressed
under the control of endogenous Bapx1 transcriptional
regulatory elements. This enabled us to isolate specifically
only cells expressing Bapx1 from these heterogeneous tis-
sues using fluorescence activated cell sorting (FACS), and
to compare the expression profiles of Bapx1 target genes
in wildtype versus loss-of-function embryos as a first step
to understanding the pleiotropic roles of Bapx1.
It is essential when unraveling the role of a transcription
factor in directing organogenesis to take the complemen-
tary and supporting roles played by other transcription
factors that are active in the same cells into consideration.
To understand such complementary roles we focused on
the vertebral column, an organ unique to vertebrates pro-
viding body structure and support, which undergoes endo-
chondral ossification of its cartilaginous structures to form
bones. To decipher the possible molecular mechanism
of chondrocyte differentiation and maturation in the
vertebral column we co-analyzed the transcription factor
Sox9, which has a major role in development and morpho-
genesis of chondrocytes [14,15].
Sox9 is a known master regulator in the osteo-
chondrogenic lineage but its co-regulatory role with
Bapx1 has not been fully explored, though some evidence
suggests that it lies in a regulatory cascade upstream of
Bapx1 [16]. To explore this, we performed similar expres-
sion profiling and genome wide binding studies in the
vertebral column of E12.5 wildtype and Sox9 null mice,
to uncover its role independently, as well as decipher
antagonistic and complementary co-regulatory roles be-
tween Sox9 and Bapx1, by comparing unique and shared
target genes. We uncovered 137 genes, which are regu-
lated by both Bapx1 and Sox9 encompassing very different
functions. Finally by combining the genome wide binding
and transcriptional profiling data we have generated agene regulatory network directed by Bapx1 and Sox9 in
the mouse vertebral column at E12.5.Results
Generation of transgenic mouse lines
With the aim of isolating Bapx1 expressing cells by FACS
for in vivo comparative gene expression analysis, we tar-
geted the endogenous Bapx1 locus with the enhanced
green fluorescent protein (EGFP) reporter gene via homolo-
gous recombination in mouse embryonic stem (ES) cells,
generating a Bapx1 wildtype (Bapx1tm2.Tlu) and a Bapx1
null (Bapx1tm4.Tlu) transgenic allele, both enabling expres-
sion of EGFP under control of the endogenous Bapx1
promoter (Figure 1A adapted from [17]). Bapx1tm2.Tlu
was designed with the reporter linked via the internal
ribosomal entry site (IRES) at the 3’ UTR of the Bapx1
locus, forming a bicistronic system with two open read-
ing frames [17-20] (Figure 1A). ES cell targeting was
verified by genomic Southern blotting (Figure 1B-C
adapted from [17]), offspring and embryos were geno-
typed by PCR (Figure 1D-E). Both Bapx1tm2.Tlu and
Bapx1tm4.Tlu showed expression of the EGFP protein in
the correct Bapx1-specific domains (Figure 2A) as previ-
ously described [6,8,11,12,17]. The Bapx1tm2.Tlu mice were
normal when compared to wildtype Bapx1+/+ littermates
[20]. Similar constructs were made for the Sox9 locus to
create Sox9tm1.Tlu [20] and Sox9−/−(EGFP) mice that are
described in detail in another manuscript.Identification of genes controlled by Bapx1 in five
different tissues
Since Bapx1 is expressed in multiple tissues in the devel-
oping mouse embryo [6,8,10,12,13], we fine dissected the
five principal Bapx1 domains prior to FACS, namely:
vertebral column, spleen, gut, forelimb and hindlimb
(Figure 2A). At E12.5 the vertebrate hindlimb is slightly
delayed in its development compared to the forelimb
[17,21-24]. To capture the distinct molecular events or-
chestrated by Bapx1 in fore- and hindlimbs, we ana-
lyzed them separately. Our microarray analysis revealed
that Bapx1 controlled very different sets of genes in all
of these five organs, with little overlap between each of
the five tissues. While Bapx1 affected a large number of
genes (with >2 fold enrichment) in the spleen (n = 980),
gut (n = 143) and vertebral column (n = 125), it controlled
only a very limited number of genes in the hind- (n = 30)
and forelimb (n = 2) (Figure 2B-C), an observation correl-
ating with the of loss-of function phenotypes in spleen,
gut and vertebral column and lack thereof in the limbs,
although Bapx1 is highly expressed during limb develop-
ment [8-10], and Bapx1 gain-of-function in the limbs re-
sults in polydactyly [13]. Mostly in vitro findings indicate
primarily a repressive function for Bapx1 [25-33] and in
Figure 1 Targeting constructs for Bapx1. (A) Wildtype Bapx1 allele and targeted Bapx1 alleles producing EGFP via IRES in the wildtype condition
(Bapx1tm2.Tlu) and via the endogenous Bapx1 promoter in the loss-of function condition (Bapx1tm4.Tlu) as adapted from [17]. Southern blot with internal
and external probes to verify the targeting event of the Bapx1tm2.Tlu (B) and Bapx1tm4.Tlu (C) alleles. Routine PCR genotyping to verify the wildtype and
targeted allele (D) and the presence and absence of the neomycin cassette (E).
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primary target genes that it is responsible for silencing.
We then focused on the nature of the regulation by
Bapx1 in each of the three tissues with a loss-of function
phenotype (spleen, gut and vertebral column) where Bapx1
obviously has an important developmental role. In two
of these tissues (spleen and gut) Bapx1 was primarily anactivator of downstream genes. We found in Bapx1-
specific spleen cells 77% of the genes (761/980) and in
Bapx1-specific gut cells 88% (126/143) of the genes
showed decreased expression in the Bapx1 null embryos.
However, in the Bapx1-specific vertebral column cells 91%
(114/125) of the genes were increased in expression in the
Bapx1 null embryo, indicating that the Bapx1 protein is
Figure 2 (See legend on next page.)
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Figure 2 Expression profiling of E12.5 Bapx1 and Sox9 producing cells from embryos. (A) Endogenous EGFP tagged E12.5 day whole
embryo showing EGFP in domains of expression of Bapx1 and the five distinct organs of expression- spleen, gut, vertebral column (VC), forelimb
(FL) and hindlimb (HL). (B) Gene expression profiling of cells sorted from five organs in the wildtype embryo as compared to null showing Bapx1
can function as either an activator or repressor in these organs. (C) Venn diagram showing almost non-overlapping regulation in Bapx1 expressing
organs. GO annotations of genes regulated by Bapx1 in vertebral column (D), gut (E) and spleen (F) where the x-axis is -log10 (p-value). (G) E12.5 day
whole embryo showing EGFP expression under the endogenous Sox9 promoter in expected domains. (H) GO annotations of genes regulated by Sox9
in the vertebral column (VC) where the x-axis is -log10 (p-value).
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column development (Figure 2B-C & Additional file 1:
Table S1) which is consistent with the in vitro findings
for Bapx1 mentioned above.
Though it is always possible in multi tissue studies that
the varying levels of gene expression changes seen in dif-
ferent organs is a reflection of the different rate of devel-
opment of each tissue, it is highly unlikely in this case
specially in the spleen and limbs. Spleen starts develop-
ing as a separate tissue from the surrounding pancreatic
mesenchyme at around E12.5 and the role of Bapx1 in
this organ is also important from this time point in de-
velopment [34]. The expression of Bapx1 in the limb is
also first detected at E11.5 [17] and hence we are looking
at organs at comparable stages of development. The ex-
pression of Bapx1 in both gut and vertebral column is first
detected at E9.5 [11,17] and comparable numbers of genes
are changing in the Bapx1 null embryo at the stage under
investigation. It is also noteworthy that almost 10 times
more genes are changing in spleen compared to the gut or
vertebral column pointing to the fact that correlation be-
tween developmental stage and impact of the loss of tran-
scription factor in an organ can be at times tenuous.
Bapx1 represses inappropriate early maturation of
chondrocytes
Bapx1 prevents early maturation of chondrocytes in the
vertebral column and its role in vertebral column devel-
opment is its most studied function. The Bapx1 null
embryos die at birth exhibiting a truncated axial skeleton
owing to the absence of ossification centers in the verte-
brae, lack of cartilage condensations and a markedly
reduced intervertebral disc formation [8-10]. During
chondrogenesis, Bapx1 is considered to primarily sup-
press the hypertrophic differentiation of chondrocytes
[16], but the genes it regulates pertaining to this function
are poorly understood. During endochondral ossification,
mesenchymal cells of the condensation differentiate into
chondrocytes, marked by their ability to secrete Collagen
II, IX, XI and Aggrecan, while repressing Collagen type I
production. Upon chondrocyte maturation, proliferation
of the chondrocytes stops and they progress to hyper-
trophy, marked by the switch to the production of type
X Collagen instead of type II. Terminal hypertrophic
chondrocytes then secrete matrix metalloproteinases todegrade the cartilage matrix, facilitating vascular invasion
that brings in osteoprogenitors for ossification [35].
During early axial skeleton development the somite
segmentation proceeds from rostral to caudal [35]. Gene
ontology (GO) analysis of data from E12.5 embryos using
“Database for Annotation, Visualization And Integrated
Discovery” (DAVID) [36,37] revealed enrichment of cartil-
age condensation/development and neuron development
genes. From this, it was evident that Bapx1 controls key
genes in cartilage development like Uncx, Chad, Ctgf and
Wwp2. We observed down-regulation of these transcripts
in the rostral vertebral column of Bapx1-null embryos by
in situ hybridization (Figure 3A-J). Thus Bapx1 impacts
the level of expression of some chondrogenic genes, but is
dispensable for their initiation of transcription. Further-
more, Bapx1 positively regulates Sox5, which regulates
extra cellular matrix genes typical for early chondrocyte
differentiation like Col2a1 and Acan, in conjunction with
Sox9 and Sox6 [38,39]. In this way, Bapx1 indirectly regu-
lates early chondrocyte differentiation.
At the same time Bapx1 suppresses neural differenti-
ation by inhibiting genes like Alcam, Ntrk3, Corin and
Dcx and prevents premature osteogenesis by inhibiting
osteoblast marker (Col1a1), cartilage degradation genes
with metallopeptidase activity (Ctsk, Adamts4, Adamts2
and Anpep) and prevents blood vessel development by
inhibiting Klf5,Vegfc and Nrp1 (FC ≤ 1.5) (Figure 2D and
Additional file 1: Table S1). Correspondingly, Ingenuity
Pathway Analysis (IPA) analysis showed enrichment of
genes in the Wnt and VEGF signaling pathways, as well
as the inhibition of matrix metalloproteases (Additional
file 2: Table S2). Wnt/B-catenin signaling is known to
suppress chondrogenesis, and cartilage degradation and
bone matrix formation are associated with chondrocyte
maturation [40]. This points out that Bapx1, which largely
functions as a repressor in the vertebral column, does not
regulate the early differentiation of chondrocytes as much
as it represses the inappropriate early maturation of these
chondrocytes.
Bapx1 controls cell survival in the spleen
Bapx1 has a strong effect on spleen morphogenesis given
the Bapx1 null embryos are asplenic at birth [8-10]. The
underlying mechanism for this phenotype was unclear as
genes controlled by Bapx1 were previously largely unknown.
Figure 3 Validation of Bapx1 target genes by RNA in situ hybridization. RNA in situ hybridization for Bapx1 regulated genes in E12.5 wildtype and
Bapx1 null embryos validating the expression profiling data for Bapx1 (A and B), Chad (C and D), Ctfg (E and F), Uncx (G and H), Wwp2 (I and J) in
the vertebral column. The arrow marks the loss of expression of the genes in the rostral part of the vertebral column. Similar loss of expression is seen
in the spleen of the null embryo for Bapx1 (K and L), Akap12 (M and N) and Gyg (O and P). Abbreviations: Sp, Spleen; St, Stomach; P, Pancreas.
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cells at E12.5 showed that wildtype Bapx1 is an activator
of a large number of genes involved in cell division and
cell cycle like Bmi1, Cdc14a, Cep55, Ccng2, Lats2, Ccne2,
Top1, Stag2, Tfdp1 and Ckap2 (Figure 2E and Additional
file 2: Table S2). Moreover, Nkx2.5, a known spleen anlage
marker and a regulator of spleen growth through the in-
hibition of cell cycle inhibitor p15, was one of the targets
in Bapx1 null embryos showing loss of expression [41].
Pdx1, another spleen development marker is also known
to regulate Nkx2.5. Bapx1 regulates Nkx2.5 as well, yet
without affecting Pdx1 itself, indicating the possible
presence of a parallel pathway that converges at Nkx2.5 to
regulate proliferation of splenic primordial cells [41]. It is
further possible that Pdx1 is upstream of Bapx1 and medi-
ates Nkx2.5 via Bapx1. Besides Nkx2.5, Slc40a1 and Bmi1
were activated by wildtype Bapx1 and the loss-of function
mouse mutants of these genes exhibit a hypoplastic spleenphenotype. Functional ablation of Slc40a1 [42] results in
increased splenocyte apoptosis while Bmi1 is a cell cycle
regulator, which shows impaired splenocyte proliferation
upon knock-out [43], suggesting that these genes also me-
diate the cell viability function of Bapx1 in the spleen.
IPA analysis predicted the proliferation of cells to be de-
creased (z-score: −3.922; p: 7.23E-11) while apoptotic genes
were enriched (z-score: 1.256; p: 9.23E-06) (Additional
file 2: Table S2). In situ hybridization showed the pres-
ence of remnant splenic primordial mesenchyme at E12.5
in Bapx1-null embryos, which is progressively lost with
development, resulting in asplenia at birth (Figure 3K-P).
Thus, the disruption of cell survival via the deregulation of
cell cycle and apoptotic genes in the splenic primordial
mesenchyme is likely causative for the hypoplasia of the
spleen at E12.5 and its complete absence at later devel-
opmental stages in the Bapx1 null mutants. IPA further
revealed the enrichment of genes of the FGF signaling
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differentiation, morphogenesis and angiogenesis. Other
enriched genes included members of the ERK/MAPK
signaling, epithelial adherens junction signaling, VEGF
signaling and epithelial-mesenchymal transition pathways
(Additional file 2: Table S2).
Validation of novel Bapx1 target genes during spleen
development
We confirmed two genes with no previously attributed role
in spleen development by section RNA in-situ hybridization
(SISH). Kinase (PRKA) anchor protein (gravin) 12 (Akap12)
previously described in the pancreas [44] was shown
here to be expressed and controlled by Bapx1 in the spleen
(Figure 3M-N). Similarly Glycogenin (Gyg) previously de-
scribed in the heart and lungs [45], was found to be
expressed and controlled by Bapx1 in the spleen as seen
by a significant decrease in expression in the E12.5 day
Bapx1 null spleen (Figure 3O-P). The entire repertoire of
genes regulated by Bapx1 in the spleen would thus serve
as a suitable database of splenic development genes for fu-
ture investigation.
Bapx1 controls enzyme inhibitors and viability in the gut
cells
Bapx1 is the mammalian ortholog of the Drosophila
bagpipe, a gene that is essential for directing the devel-
opment of the fly visceral mesoderm into gut musculature
[46,47]. In contrast, Bapx1 does not seem as critical during
morphogenesis of the mammalian gut, given most of the
previous knock-out studies failed to report a significant gut
phenotype, except for a shortening of the antrum-pylorus
segment and the loss of the pyloric constriction [8-10].
Bapx1 expressing cells are reportedly present in the gut
mesenchyme with a rostral boundary in the hind stom-
ach, near the junction of the gastric corpus and antrum
[11]. By analyzing genes under the control of Bapx1 we
defined its potential role in the gastrointestinal tract. Our
GO annotation of genes clearly indicated that Bapx1
primarily controls genes involved in endopeptidase and
other enzyme inhibitor activities (Figure 2E). These in-
clude KngI, Ambp, Serpina1B, SerpinaA6, Spink3 and
Itih3 among others. In analogy to the spleen our IPA
analysis revealed that Bapx1 regulates a significant pro-
portion of proliferation (z-score: −3.054; p: 2.22E-05) and
apoptotic genes (p: 3.01E-03) in the gut, thus explaining
the shortening of the antrum-pylorus segment in the null
embryo (Additional file 2: Table S2). Our genome wide
transcriptional profiling revealed genes previously un-
known to be controlled by Bapx1 in the gut and the control
of a physiological activity (enzyme inhibitory action) that
has not been attributed to it previously. Furthermore, sig-
naling pathways such as ERK/MAPK signaling, VEGF sig-
naling and the epithelial-mesenchymal transition pathwaywere enriched in the gut similar to our observations in the
spleen (Additional file 2: Table S2).Bapx1-Sox9 act synergistically in the developing vertebral
column
Previous in vitro analyses showed Bapx1 and Sox9 connect
in an auto-regulatory loop and Sox9 repressing Runx2 via
Bapx1, thereby preventing the inappropriate hypertrophic
differentiation of chondrocytes [16]. Hence we investi-
gated the regulatory targets of Sox9 in the developing
E12.5 vertebral column in vivo. Similar to our work re-
garding Bapx1, we enriched for Sox9-specific cells from
the vertebral column of Sox9+/tm1.1Tlu and Sox9−/−(EGFP)
E12.5 embryos using FACS (Figure 2G). Our microarray
data on the Sox9-specific cells revealed that the Sox9
protein, unlike Bapx1, is neither an overt activator nor
a repressor of transcription in the vertebrate column as
42.2% (1514/3593) genes showed decreased expression
(FC1.5; p ≤ 0.05) compared to 57.7% (2073/3593) showing
increased expression (FC1.5; p ≤ 0.05) in the Sox9 null
embryo relative to the Sox9 wildtype embryo (Additional
file 1: Table S1). IPA of these Sox9 controlled genes revealed
that most had known roles in chondrocyte differentiation
(p: 3.43E-06), proliferation (p: 3.82E-28) and apoptosis
(p: 3.92E-14) (Figure 2H and Additional file 2: Table S2)
consistent with the known role of Sox9 as a master regula-
tor of osteo-chondrogenesis. Though many of the down-
stream genes are known to be involved in chondrogenesis
through in vitro studies, our data demonstrates that Sox9
regulates these genes in vivo in the developing mouse
embryo at E12.5, a time when the developing skeleton
is transitioning from mesenchymal condensations to a
chondrogenic framework. Similar to the pathways regu-
lated by Bapx1 in the vertebral column, IPA analysis
for Sox9 regulated genes showed enrichment of the
Wnt/B-Catenin and VEGF signaling pathways, and the
inhibition of matrix metalloproteases (Additional file 2:
Table S2).
With Bapx1 and Sox9 functioning in the same tissue
and regulating similar pathways, the question arose whether
these two transcription factors act on the same set of genes
in a co-regulatory manner. Comparing Sox9 controlled
gene expression with Bapx1 target genes allowed us to filter
for chondrogenic genes, as Bapx1 is naturally absent in the
neural tube. We focused on three sets of genes: (1) com-
mon genes that are activated by Sox9 but repressed by
Bapx1, (2) genes repressed by both and (3) genes activated
by both. For analysis of gene co-regulated by Sox9 and
Bapx1 we have used a cut off of FC1.5 to make a larger
gene set to avoid overlooking any gene which might be
strongly regulated by one and weakly by other. We found
59 genes to be repressed by Bapx1 and activated by Sox9
all primarily involved in neurogenesis and neuronal
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and Additional file 3: Table S3).
Analyzing genes repressed by both transcription factors
in the vertebral column, we found 72 genes, which in-
cluded the osteogenic factor Col1a1, cartilage degrading
metalloproteases (Mmp11, Adamts2, Adamts4) and most
highly enriched, genes controlling blood vessel develop-
ment (Vegfc, Emcn, Nrp1), an essential process during
chondrocyte maturation [48,49] (Figure 4B and Additional
file 3: Table S3 ). Though the role of Sox9 as a repressor of
cartilage vascularization has been shown recently [50], our
data suggests that Bapx1 plays an equally critical role in
this process. Thus by repressing these genes at an early
time point in development it prevents premature ossifica-
tion of the developing vertebral column. Moreover, Bapx1
and Sox9 function as activators on only six common target
genes, including Sox5, Wwp2, Chad and Ctgf, which are all
known to be involved in cartilage development [14,50-52]
(Additional file 3: Table S3).
Surprisingly, we did not detect Bapx1 as one of the down-
stream targets of Sox9 or vice versa at E12.5 in the vertebral
column (Additional file 1: Table S1 and Additional file 3:
Table S3). However, we found Sox9 to be downstreamFigure 4 Co-regulation by Bapx1 and Sox9. (A) Venn diagram showing the
vertebral column of E12.5 wildtype embryos and the GO annotation of those c
showing the 72 common genes repressed by both Sox9 and Bapx1 in the vert
common genes.of Bapx1 in the spleen and gut tissue. Besides, Bapx1 was
clearly upregulated in the Bapx1-null embryos in the ver-
tebral column (Figure 3A, B), indicating potential auto-
regulation.
Genome wide binding of Bapx1 and Sox9 proteins to
DNA target sites in the vertebral column
The pool of differentially expressed genes from the expres-
sion profiling consisted of target genes that were regulated
directly by Bapx1 and Sox9, and indirect target genes
whose expression was altered owing to the loss of these
two transcription factors affecting their upstream regula-
tors (secondary effectors). To find genes directly controlled
by Bapx1 and Sox9 proteins during vertebral chondrogene-
sis, we performed chromatin immunoprecipitation sequen-
cing (ChIP-Seq) on vertebral columns dissected from E12.5
embryos. For Sox9, we performed ChIP-Seq with an anti-
Sox9 antibody. However for Bapx1, owing to the absence
of a suitable ChIP grade quality Bapx1 antibody, a mouse
line with a S-Peptide and Calmodulin binding peptide
(CBP) epitope tagged to Bapx1 at its N-terminus was
generated (Figure 5A and Additional file 4: Figure S1)
similar to other work we have described [53-56]. S-peptide59 common genes activated by Sox9 and repressed by Bapx1 in the
ommon genes, which are primarily neuronal markers. (B) Venn diagram
ebral column of E12.5 wildtype embryos and the GO annotation of those
Figure 5 (See legend on next page.)
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Figure 5 In vivo ChIP-Seq for Bapx1 and Sox9 in the vertebral column of E12.5 embryos. (A) Targeting of the endogenous Bapx1 locus
with a CBP- S peptide tag to generate N-terminal tagged BAPX1 protein. (B) The Bapx1 binding site motif enriched in the top 1000 binding sites
from ChIP-Seq. (C) Whole genome binding site distribution for Bapx1 in the vertebral column of E12.5 wildtype embryos. The number on top of
each peak represents the total number of peaks found at that distance from the TSS. Note that most peaks are found distally from the TSS.
(D) GO annotation of the nearest genes to the peak shows enrichment of genes expressed in chondrocytes. (E) Similar binding site distribution for
Sox9 and (F) GO annotation for the nearest genes showing enrichment of genes expressed in chondrocytes, x-axis is -log10 (p-value).
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routinely used for protein purification purposes [57-59]
and owing to their small size suitable for endogenous
tagging of transcription factors in the mouse [53,54]. Their
absence from the wildtype mouse proteome allows for
highly specific ChIP. The homozygous Bapx1 protein
tagged mice we generated were phenotypically normal
compared to their wildtype littermates, assuring normal
biological activity of the tagged protein and thus allowed
us to use the S-peptide antibody to pull down tagged
Bapx1.
Using the model-based analysis for ChIP-Seq (MACS)
algorithm [60] we detected 2815 Bapx1 peaks with 19%
(540) of the binding sites located on the transcription
start sites (TSS) of genes (Figure 5C). Interestingly a large
proportion of the binding sites were distal from the TSS,
with 37% (1052) located at >25 kb distally in the intergenic
region and 26% (722) located >25 kb in the intragenic re-
gions (Figure 5C). Likewise for Sox9, we identified 3722
peaks. Similar to Bapx1, most of the binding sites were lo-
cated distal to the TSS, with only ~ 10% (359) of the Sox9
binding sites at the TSS of various genes and 66% (2470)
of the binding sites more than 25 kb distal to the TSS
(Figure 5E). This shows that in midgestation embryos,
critical transcription factors like Bapx1 and Sox9 tend
to bind primarily to distal regulatory elements in order
to direct downstream gene expression in target cells
and tissues rather than activating transcription at the
TSS. To ascertain which are potential Bapx1 direct tar-
gets in the vertebral column we looked at genes that
are differentially expressed (fold change = 1.5) in the micro-
array dataset for the vertebral column and discovered that
of all the genes that have a binding site within 100 kb of
their TSS 84% are up-regulated in the Bapx1-null. This
adds confidence to the data that the Bapx1 protein pri-
marily acts as repressor in the vertebral column (Additional
file 5: Table S4).
We identified the previously reported Bapx1 binding
motif T(G/A)AGTG [28], enriched in about 40% of the
Bapx1 binding sites in the genome (Figure 5B) specific-
ally near genes controlling cartilage and bone morpho-
genesis (Figure 5D). Notably, this motif was reported to
be involved in chondrogenesis in vitro, in cell culture and
chicken embryo explant assays [28,29,61]. Our data is the
first to demonstrate the in vivo binding of Bapx1 to gen-
omic DNA by this motif in mouse embryo chondrogeniccells. We further validated the Bapx1 binding motif by
performing electrophoretic mobility shift assays (EMSA)
with four randomly selected genomic regions containing
this motif (Additional file 6: Table S5). This allowed us to
test the binding specificity of the motif in its native con-
text. All four of the randomly chosen genomic regions
containing the motif were able to bind Bapx1 in vitro
(Additional file 7: Figure S2A). To further confirm the spe-
cificity of the motif, we mutated all the nucleotides of the
core sequence of one of the regions by transversion and
noted a complete abrogation of binding (Additional file 7:
Figure S2B). We ascertained the specificity of this binding
of the probe to Bapx1 using a supershift assay. We gener-
ated NIH3T3 cells overexpressing V5-tagged Bapx1 and
used an anti-V5 antibody on nuclear extract for specificity
and an anti-Flag antibody as a non-specific control. Our
results showed a supershift with the anti-V5 antibody,
whereas the addition of anti-Flag antibody had no effect
on the shift (Additional file 7: Figure S2B). We further
analyzed if some of the Bapx1 bound regions could act as
enhancers in a transactivation assay using a luciferase
reporter. We cloned seven randomly selected genomic
regions (including the four tested in EMSA) (Additional
file 6: Table S5) in a minimal promoter driven luciferase
vector (pGL4.23) and co-transfected it with the V5-tagged
Bapx1 vector into NIH3T3 cell lines. Five out of the seven
regions showed activity over the basal level thus acting as
an enhancer. To further test if the core-binding motif for
Bapx1 was necessary and sufficient for this activity we
used mutated oligonucleotides for the core sequence in
two of the regions. The mutated oligonucleotides failed to
drive expression over the basal level, thus proving that the
core Bapx1 motif is the essential component of these en-
hancers (Additional file 7: Figure S2C). Similarly, most of
the genes nearest to the Sox9 binding regions were in-
volved in chondrogenesis, validating the specificity of the
data (Figure 5F). We also identified the DNA binding motif
for Sox9 (A/T)(A/T)CAA(A/T)G that had been previously
identified mostly by in vitro studies [62-64]. Our data
shows that Sox9 binds near genes involved in chondrogen-
esis in the developing mouse embryo by this same motif.
Direct co-regulation by Bapx1 and Sox9 in the vertebral
column
Next we established how many of the genes in these groups
have binding sites for both transcription factors within
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Sox9 and repressed by Bapx1, 86% (51/59) had both the
Bapx1 and Sox9 binding sites within 200 kb of their TSS
(Additional file 8: Table S6). These genes represent poten-
tial primary targets of Bapx1 and Sox9, which are under
opposite regulatory pressure in the vertebral column to
maintain a distinct neuronal and osteo-chondrogenic
identity in the developing embryo, they include genes
like Gata3, Ctnna2, Nrn1 and Dcx, whose knockouts have
a reported neuronal phenotype [65-69] but have never
been associated with a regulation by either Sox9 or Bapx1.
Our dataset thus connects Bapx1 and Sox9 downstream
genes with a dual regulatory mechanism. Similarly, 78%
(56/72) of the genes repressed by both Sox9 and Bapx1
had binding sites for both Sox9 and Bapx1 within 200 kb
of their TSS (Additional file 3: Table S3 and Additional
file 8: Table S6). These genes are also potential primary
targets of both Sox9 and Bapx1, but repressed by both.
This group includes the osteogenic, metalloproteinase
and angiogenesis genes Col1a1, Mmp11, Adamts4, Ctsk,
Emcn and Nrp1. We looked for binding sites that were
overlapping for both the transcription factors but failed to
find any at this stage of development. This was not en-
tirely unexpected since both are large transcription factors
with distinct motifs thus it is slightly unlikely they could
occupy a single enhancer without causing steric hindrance
at the same time in development.
Our results show that combining genome wide data for
binding and transcriptional profiling of two critical
transcription factors (Bapx1 and Sox9) in a single organ
can lead to a detailed understanding of the diverse levels
of regulation involved in its organogenesis. Some neuronal
genes were found under a competing control mechanism,
receiving both positive and negative inputs: primarily
neuronal genes and genes controlling processes essential
for chondrocyte maturation were repressed in chondro-
cytes and those promoting chondrogenesis were activated
by both Bapx1 and Sox9 (Figure 6A). Finally by assem-
bling information from all the genes regulated by Bapx1
and Sox9 either directly or indirectly a large-scale in-
tegrative gene regulatory network could be delineated
(Figure 6B).
Discussion
It is becoming increasingly clear that an in-depth under-
standing of organogenesis in vertebrates will require
comprehensive systems biology approaches to tease out
all the players in various pathways and integrate them
into a mechanistic network. Gene expression profiling
coupled with genome wide binding studies for particular
organs have over the years shed some light on these
complex processes [70,71]. However, transcriptome ana-
lysis of an entire tissue or organ only gives a broad and
often confusing picture of the precise transcriptionalchanges taking place during development owing to a large
heterogeneity of different cell types that comprise individ-
ual tissues that make up a functional organ. By conducting
expression profiling only on cells that express a particular
set of transcription factors we generated a highly focused
dataset elucidating pleiotropic roles played by the tran-
scription factors in organogenesis.
We have analyzed five different organs expressing the
Bapx1 gene to explain the disparate roles it plays in each
of them. Although the pleiotropic role of Bapx1 was known
and many phenotypes defined, our approach is the first
large-scale effort looking at all the major tissues expressing
Bapx1. This allowed us to make connections between
many new genes previously unknown to be controlled
by Bapx1. The large scale dataset generated enabled us
to place these genes within pathways they control, es-
sentially explaining the lack of a limb phenotype, the
absence of an overt morphological phenotype in the gut
and the impact on cell cycle regulation in the spleen
leading to asplenia in the Bapx1 loss-of-function mice.
Importantly, Bapx1 largely regulates different genes and
pathways in the different tissues to execute its pleiotropic
roles. Interestingly, spleen and gut tissue, which are closely
associated during gastrointestinal development [72] share
more similar pathways with each other than with vertebral
column tissue. Indeed, among the five tissues, spleen
and gut share the most number of common genes. In-
triguingly, while Bapx1 represses VEGF signaling in the
vertebral column and gut, it is largely activated in the
spleen. The spleen is a repository of red blood cells and
its development involves vascularization that allows the
infiltration of lymphoid progenitors as early as E12.5-
E13.5 [73]. Hence, positive regulation of angiogenesis in
the spleen is not too surprising. At the same time, consist-
ent with its role in preventing premature endochondral
ossification, Bapx1 inhibits VEGF signaling in the vertebral
column.
The formation of gene regulatory networks in verte-
brate development continues to be a long arching goal
of developmental biology. Yet, to establish such detailed
maps, many times input from more than one transcrip-
tion factor is required. Hence, we co-analyzed in similar
fashion cells specific for Sox9, another key transcription
factor during chondrogenesis and vertebral column devel-
opment. Combining the genes regulated by Bapx1 and
Sox9 in the vertebral column we have generated a network
of genes activated and/or repressed by these transcription
factors during the fine tuned process of organogenesis.
We have identified 137 genes co-regulated by these two
transcription factors providing insight into some of the
mechanisms employed during chondrocyte maturation;
there is a group of neuronal genes, which are acted upon
antagonistically by Bapx1 and Sox9, chondrogenic dif-
ferentiation genes which are activated by both Sox9 and
Gbx2, Dbx, Nrn1, Ctnna2 
A
B
Bapx1 Pcolce2, Chad, Id4Ctgf, Sox5, Wwp2 
Col1a1, Adamts2, Adamts4
















Figure 6 (See legend on next page.)
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Figure 6 A gene regulatory network in vertebral column driven by Bapx1 and Sox9. (A) Three layer mechanism of genomic control in the
vertebral column by Bapx1 and Sox9. Bapx1 suppresses neuronal genes whereas Sox9 activates them; both activate chondrogenic genes whereas
both suppress genes involved in osteogenesis, cartilage degradation and blood vessel development. (B) A large gene regulatory network in the
vertebral column of genes that are either activated (green lines) or repressed (red lines) by Sox9 and Bapx1. Each blue dot represents a gene and
the common regulated genes are in the center on the network connected to both Sox9 and Bapx1.
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both Sox9 and Bapx1 that are involved in processes
essential for hypertrophic chondrocyte differentiation.
Furthermore, Bapx1 and Sox9 contribute to several
similar pathways during vertebral column development,
especially the repression of osteogenic differentiation and
cartilage degradation. We also studied the genome wide
binding of Bapx1 and Sox9 in vertebral column tissue to
identify potential primary target genes. Our ChIP-Seq data
revealed that although Bapx1 and Sox9 bound to the TSS
of some genes, the majority of the genes regulated by
these two transcription factors had their binding sites
distal to the TSS, highlighting the fact that during the
midgestation development in mouse embryos many
critical transcription factors bind to distal cis-regulatory
elements.
Conclusions
In all we have managed to create a comprehensive list of
genes controlled by a single transcription factor namely
Bapx1 from five different tissues, explaining its diverse roles
and the various genetic pathways Bapx1 contributes to.
This is the first study analyzing all major Bapx1 dependent
organs in molecular detail and providing explanations for
the phenotypes observed in the loss-of-function animals.
Many of the here identified target genes were previously
unknown to be either directly or indirectly regulated by
Bapx1 owing to a lack of feasible strategies for determin-
ing downstream effectors on a genome wide scale. This
genomic resource and the underlying mechanisms uncov-
ered will form the basis for a deeper understanding of the




All animal procedures were performed according to the
Singapore A*STAR Biopolis Biological Resource Center
(BRC) Institutional Animal Care and Use Committee
(IACUC) guidelines which are set by the National Advisory
Committee for Laboratory Animal Research (NACLAR).
The IACUC protocols employed were reviewed and ap-
proved by the aforementioned committee before any
animal procedures were undertaken for this study described
here (IACUC Protocol No: 110689 and 110648). The
mouse strains used in this study were housed, maintained
and provided by the A*STAR Biopolis Biological ResourceCenter. The lines described here will be made available
to the research community upon acceptance of the
manuscript.Gene targeting and mouse generation
The over 160 kb murine BAC clone RP24-148P5 contain-
ing genomic C57BL/6 J DNA flanking the Bapx1 gene
was obtained from the BACPAC Resources Centre at
Children’s Hospital Oakland Research Institute (CHORI)
and modified using a Quick and Easy BAC modification
kit (Gene Bridges) according to the manufacturer’s instruc-
tion. The Bapx1tm2.Tlu allele was generated as described
in [17] to generate wildtype mice expressing EGFP in
the Bapx1 domains. The Bapx1tm4.Tlu allele was generated
by inserting the EGFP-FRT-PGK-gb2-Neo-FRT cassette
immediately after the translational start codon of Bapx1,
deleting 90 bp of the endogenous sequence to create the
Bapx1 null mice expressing EGFP. The gene targeting
events were confirmed by Southern blotting and for
each allele, at least two independent ES cell clones with
normal karyotype were subsequently microinjected into
2-8-cell stage embryos isolated from C57BL/6 mice to
generate chimeric mice as previously described [74]. The
chimeric mice were bred to wildtype mice to generate
stable lines. The FRT-flanking neomycin cassette in the
targeted Bapx1 allele was removed by breeding to the
FLPe–deleter mice 129S4/SvJaeSor-Gt(ROSA)26Sor tm1
(FLP1)Dym /J (Stock # 3946) from Jackson Laboratories
[75,76]. Routine PCR genotyping of Bapx1 lines was
performed as essentially described in [17].Sorting Bapx1-EGFP cells from mouse embryos
The mouse embryos were harvested in ice-cold Leibovitz
L-15 medium (Gibco) at E12.5. Embryos expressing EGFP
in the Bapx1-expression domains were identified under
a fluorescent dissection microscope (Leica). The embryos
were dissected to separate out the vertebral column, spleen,
gut, hindlimb and forelimb, which were then separately
dissociated into single cells with a solution comprising
of 100U/ml Collagenase I & II, 50U/ml DNAse and 0.05%
Trypsin (Invitrogen). The cells were filtered serially through
a 100uM and 40uM cell strainer, and centrifuged at
2000 rpm for 5 min. The cell pellet was resuspended
in 5% FBS, 4 mM EDTA in Leibovitz L-15 medium for
cell sorting using FACSAria (BD Biosciences).
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Total RNA was extracted form 4 biological replicates
for both wild type and null embryos for each of the tissues.
Each biological replicate was isolated from each popula-
tion of sorted cells using TRIzol (Invitrogen) followed
by the RNeasy Micro Kit (Qiagen). Sample integrity was
assessed using an Agilent 2100 Bioanalyzer (Agilent
Technologies). 25 ng total RNA from each sample was
labelled using TargetAmp™-Nano Labelling Kit for Illumina
Expression BeadChip (Epicentre Biotechnologies) and
hybridized on MouseWG-6 v2.0 Expression BeadChip
microarrays (Illumina) according to Illumina guidelines.
GenomeStudio software (Illumina) was used to prepare
background-subtracted data. The background-subtracted
data was then imported into Partek Genomics Suite
(Agilent) and the data normalized. The probe intensities
from various biological replicates were normalized using
scale normalization using median absolute deviation as a
spread measure. This was further filtered on percentile
(lower 20 and upper 100) by expression of probe sets
without averaging over replicates. These consistent probe
sets, which passed this filter, were further used to calculate
gene expression changes between different conditions.
ANOVA with nominal alpha value set to 0.05 was then
used to determine the probe sets significantly different
between the different genotypes compared. Benjamini
and Hochberg Multiple testing correction was applied
to reduce the false positive rate, and probe sets with ex-
pression fold change >2.0 or >1.5 between the different
genotypes were selected for further validation and ana-
lyses. All data has been deposited in Gene Expression
Omnibus (GEO) under accession number GSE35877.
Ingenuity Pathway Analysis (Ingenuity® Systems, www.
ingenuity.com) and DAVID (http://david.abcc.ncifcrf.gov/)
gene ontology analyses were performed using the respect-
ive web-based tools.
ChIP-assay and peak calling
For Bapx1 ChIP vertebral columns from ~100 E12.5
(both S-peptide tagged and wildtype each) embryos were
dissected and 2 mg of chromatin was used for ChIP as
previously described [77] with anti S-Peptide antibody
(Bethyl laboratories, A190-134A). For Sox9 ChIP anti-Sox9
antibody (R&D Systems, AF3075) was used for immuno-
precipitation. 10-15 ng of purified ChIP DNA from each
sample was used to synthesize the sequencing library
as instructed by the ChIP-Seq DNA sample Prep Kit
(Illumina). The libraries were then subjected to Solexa
sequencing according to Illumina’s instruction. Sequence
reads produced by Illumina Genome Analyzer II/IIx that
passed the signal purity filtering were mapped to the
mouse genome mm9, using the Illumina Genome Analyzer
Pipeline. All uniquely mapped reads that are with two or
fewer mismatches were retained. Genomic binding sites inthe ChIP-Seq datasets were identified using the peak
calling algorithm MACS (version 1.4.0 beta) with default
settings (band width = 300, model fold = 10, 30, p-value
cutoff = 1.00e-05, range for calculating regional lambda =
1000 and 10000 bps) [62]. The corresponding control
libraries were used for all the peak callings. For Anno-
tation of the ChIP-Seq peaks, first the TSS of the near-
est Refseq gene nearest to peaks were found, then the
distance from nearest TSS was found and reported. If
the peaks resided in intragenic region of nearest gene it
was called “intragenic”, otherwise “intergenic”. If the
peaks resided within 5000 bp of TSS they were called
as “promoter” peaks. All data has been deposited in Gene
Expression Omnibus (GEO) under accession number
GSE35877 and also provided in BED format (Additional
file 9: Table S7).
Motif analysis
Peaks called by MACS were ranked according to the
total tags count as defined in the MACS output file. The
top 200 peaks were used for motif analysis and the repeat
masked genome sequence +/− 50 bp from the summit of
these 200 peaks was downloaded from the UCSC genome
browser (http://genome.ucsc.edu/). After masking repeats
to N, we performed de novo motif finding using MEME
ver. 4.3.0 with the sequences. MAST was used to scan for
the occurrences of the primary de novo motif obtained
using all the sequences +/−50 bp of the ChIP-Seq peak
summit. The cut off for motif match in MAST used was
the default p = 1.0e-4.
Gene enrichment test for regions bound by Bapx1 and
Sox9
We submitted the analyzed ChIP-Seq data as bed format
to Genomic Regions Enrichment of Annotations Tool
(GREAT) [78] version 1.8 with the following parameters-
Species assembly-mm9 and Association rule-Single nearest
gene: 100,000 bp maximum extension, curated regulatory
domains included.
RNA in-situ hybridization
In situ hybridizations were performed using DIG labeled
RNA probes as previously described [17]. For analysis of
the vertebral column the E12.5 embryos were sectioned
through the sagittal plane and for analysis of the spleen
through the dorsofrontal plane.
Luciferase reporter assay and EMSA
Luciferase assay was performed to determine the tran-
scriptional activation property of some of the binding
sites bound by Bapx1. Mouse Bapx1 full-length cDNA
(40131175, Openbiosystems) was cloned upstream of the
V5-tag in the pcDNA6/V5-HisABC vector (Invitrogen).
400 ng of firefly luciferase vector (pGL4.23, Promega
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of Bapx1 expression vector, and 2 ng of Renilla luciferase
vector (transfection control) was transiently transfected
into mouse fibroblast cell line (NIH/3 T3) (5 – 6 × 104
cells/well) using 6ul of FuGENE HD transfection reagent
(Roche Diagnostic, USA), in 100 μl of OPTI-MEM I
medium (Invitrogen, USA). The cells were grown for
48 hours and the luminescence was measured using Dual
Luciferase Reporter Assay System on a Glomax multide-
tection system Luminometer as per manufacturer’s instruc-
tions (Promega Corporation).
Electrophoretic mobility shift assays were performed
as previously described [79]. Briefly V5 tagged Bapx1
vector was transfected in NIH/3 T3 cells using FuGENE
HD transfection reagent. Cells were harvested 48 hours
post transfection and nuclear proteins were extracted
using the NE-PER nuclear and cytoplasmic extraction
kit (Thermo Scientific, USA). EMSAs were carried out
using 10 nM DNA probes modified with 5’ Cy5 labels
(Sigma Proligo) incubated with 10ug nuclear extracts. For
supershift assays the probe and the nuclear extract were
incubated with 1ug of V5 antibody (ab15828, Abcam) or
Flag (F7425, Sigma) was used as a non-specific antibody.
Gene regulatory network
The gene regulatory network was constructed using Cytos-
cape [80], by considering all genes that are showing >1.5 fold
change in the microarray (activated as well as repressed).
Additional files
Additional file 1: Table S1. In vivo gene expression changes. Obtained
from microarrays on gene specific cell lineages obtained from wildtype
and loss of function vertebrate columns at E12.5. Gene expression changes
in all five tissues with >2 fold difference for Bapx1 and >1.5 fold difference
for Sox9 and Bapx1.
Additional file 2: Table S2. Ingenuity Pathway Analysis. Ingenuity
Pathway Analysis of Bapx1 in the spleen, vertebral column and gut and
Sox9 in the vertebral column.
Additional file 3: Table S3. Genes co-regulated by Sox9 and Bapx1 in
vertebral column. Common genes either repressed by both Sox9 and
Bapx1, activated by Sox9 and repressed by Bapx1 or activated by both in
the E12.5 vertebral column >1.5 fold.
Additional file 4: Figure S1. Targeting of the murine Bapx1 locus.
N-terminal targeting of the murine Bapx1 locus with an S-peptide/CBP
tag.
Additional file 5: Table S4. Genes with Bapx1 binding site within
100 kb of the TSS.
Additional file 6: Table S5. Probe and DNA binding sequence for the
EMSA and luciferase assays.
Additional file 7: Figure S2. EMSA and Luciferase assay Bapx1 bound
genomic regions. (A) EMSA gel showing shifting of four different probes
(black arrow) containing genomic loci with the Bapx1 binding motif in
presence of nuclear extract containing over-expressed V5-tagged Bapx1.
FP, free probe. (B) Gel showing mutant probe (MT) with no shift, and
incubation with V5 antibody (V5Ab) resulting in a supershift (black
arrow) and no supershift with a non-specific Flag antibody (FlagAb).
The white arrow indicates the shift. (C) Luciferase assay with sevengenomic regions containing the Bapx1 binding motif (R1-R7) and two
mutant probes (M1-M2) for regions R3 and R7.
Additional file 8: Table S6. Binding site distance from the TSS. Binding
site distance from the TSS for Bapx1 and Sox9 near genes co-regulated
by both in vertebral column.
Additional file 9: Table S7. ChIP coordinates in BED format.
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